NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript February 17, 2026 NeoGenomics, Inc. misses on earnings expectations. Reported EPS is $-0.38403 EPS, expectations were $0.04. Operator: ...

NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare ...

NeoGenomics Inc (NEO) reports robust revenue growth and outlines strategic plans to enhance market presence and profitability.

Q4 2025 Earnings Call February 17, 2026 8:30 AM ESTCompany ParticipantsKendra Sweeney - Vice President of Investor Relations ...

NeoGenomics Inc (NASDAQ:NEO) on Tuesday posted fourth-quarter results that topped Wall Street estimates, though shares declined sharply in early trading as investors weighed the company’s growth ...

Kendra Webster with NeoGenomics, Inc. The floor is yours. With me today to discuss the results are Anthony P. Zook, Chief ...

For the full year 2025, consolidated revenue increased 10% to $727 million, while the company reported a net loss of $108 million, up from $79 million in 2024. Adjusted EBITDA for 2025 was $43 million ...

The Q4 earnings report for NeoGenomics (NASDAQ: NEO) was released on Tuesday, February 17, 2026 at 07:05 AM. Here's what ...

NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the ...

FORT MYERS, Fla. (AP) — FORT MYERS, Fla. (AP) — NeoGenomics Inc. (NEO) on Tuesday reported a loss of $9.9 million in its ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue ...